How to Get Tresiba (Insulin Degludec) in New York

What Is Tresiba and Why New York Patients Request It

Tresiba is a basal insulin with a half-life of approximately 25 hours and a duration of action exceeding 42 hours, making it the longest-acting insulin currently approved by the FDA. New York patients with type 1 or type 2 diabetes frequently request it because its flat pharmacokinetic profile produces less day-to-day glucose variability than insulin glargine U-100. The FDA approved insulin degludec in September 2015 for adults and later expanded the label to include pediatric patients aged 1 year and older. [1]

The DEVOTE trial (N=7,637) published in the New England Journal of Medicine in 2017 compared insulin degludec with insulin glargine U-100 in high-cardiovascular-risk patients with type 2 diabetes. Degludec was non-inferior for major adverse cardiovascular events (MACE) and produced a 40% relative reduction in confirmed nocturnal severe hypoglycemia (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001). [2] That hypoglycemia advantage is often the primary clinical reason a New York prescriber will choose Tresiba over older basal insulins. [3]

Dosing flexibility also matters for working New Yorkers. The label permits dose timing to shift by up to 8 hours from the usual injection time on a given day, which suits shift workers and frequent travelers. [1] Available concentrations are U-100 (100 units/mL) and U-200 (200 units/mL) FlexTouch pens, with the U-200 pen delivering up to 160 units per injection and useful for highly insulin-resistant patients. [4]

Step 1: Choose a Prescriber Licensed in New York

Any licensed New York prescriber with DEA registration and a New York State Education Department (NYSED) registration can write a Tresiba prescription. That includes MDs, DOs, nurse practitioners with full prescriptive authority (Article 139 of New York Education Law), and physician assistants with a supervising agreement on file. [5]

Telehealth prescribing is fully legal for Tresiba in New York. The New York State Department of Health confirmed that audio-video telehealth visits satisfy the patient-prescriber relationship requirement for Schedule III-V and non-scheduled drugs, and insulin is non-scheduled. [6] A prescriber does not need to see you in person first, provided they conduct a synchronous audio-video encounter and document a clinical assessment.

When selecting a telehealth provider, confirm two things before booking: the clinician holds an active New York license (searchable at the NYSED Office of the Professions license verification portal), and the platform transmits prescriptions electronically to New York-licensed pharmacies. HealthRX connects New York patients with board-certified endocrinologists and internists who specialize in basal insulin titration.

Step 2: Gather the Labs Your Prescriber Will Need

Prescribers cannot safely initiate basal insulin without baseline metabolic data. Most New York telehealth endocrinology practices require the following before or at the time of the first Tresiba visit.

Mandatory labs:

• Hemoglobin A1c (HbA1c): establishes baseline glycemic control. The American Diabetes Association 2024 Standards of Care define an HbA1c target of <7.0% for most non-pregnant adults, with individualized targets for older adults or those with hypoglycemia unawareness. [7]
• Fasting plasma glucose or continuous glucose monitor (CGM) download: needed for initial dose calculation.
• Basic metabolic panel (BMP): renal function affects insulin clearance and metformin co-prescription decisions. [8]
• Complete blood count (CBC): rules out anemia that could falsely lower HbA1c. [9]

Strongly recommended:

• Fasting lipid panel: cardiovascular risk stratification per ACC/AHA 2019 guidelines. [10]
• Thyroid-stimulating hormone (TSH): uncontrolled hypothyroidism worsens insulin resistance. [11]
• Urine albumin-to-creatinine ratio (UACR): screens for diabetic nephropathy per ADA Standards of Care. [7]

Labs drawn within 90 days are usually accepted. Quest Diagnostics and LabCorp both have dozens of New York City and upstate draw sites; results typically post to patient portals within 24 to 48 hours. If you have no recent labs, a HealthRX care coordinator can send a standing lab order to a location near you before your scheduled visit.

Step 3: Complete Your Telehealth Consultation

The telehealth visit itself runs 20 to 45 minutes for a new Tresiba patient. Your prescriber will review your lab results, current medications (particularly metformin, SGLT-2 inhibitors, and GLP-1 receptor agonists that may affect insulin dosing), hypoglycemia history, weight, and renal function. [12]

Dose initiation follows published protocols. For type 2 diabetes naive to basal insulin, the ADA 2024 Standards of Care recommend starting at 10 units once daily or 0.1 to 0.2 units/kg/day, then titrating by 2 units every 3 days to reach a fasting glucose target of 80 to 130 mg/dL. [7] For type 1 diabetes, total daily dose is split approximately 50% basal and 50% prandial, with the basal component initiated at 0.2 to 0.4 units/kg/day. [13]

The prescriber will also counsel on injection technique, hypoglycemia recognition and treatment (15 grams of fast-acting carbohydrate for blood glucose <70 mg/dL), storage (refrigerate unopened pens at 36 to 46 degrees Fahrenheit; in-use pens can be kept at room temperature up to 86 degrees Fahrenheit for 56 days), and sick-day rules. [1]

A structured titration framework used by the HealthRX endocrinology team for new Tresiba patients in New York involves three phases: (1) a 10-unit start dose with weekly fasting glucose review via CGM or log, (2) a 2-unit-per-3-day uptitration until two consecutive fasting readings fall between 80 and 130 mg/dL, and (3) a 90-day stability visit to reassess HbA1c and renal function before any further dose change. This phased approach reduces the risk of nocturnal hypoglycemia during the titration window, a concern supported by DEVOTE sub-analyses showing that nighttime hypoglycemia is most common in the first 16 weeks of basal insulin initiation. [2]

Step 4: Obtain Your Prescription and Manage Prior Authorization

After the visit, your prescriber sends an electronic prescription to your preferred New York pharmacy. If you carry commercial insurance or New York Medicaid, prior authorization (PA) is almost always required before the pharmacy can dispense Tresiba.

New York Medicaid (Medicaid FFS and Managed Medicaid):

New York Medicaid covers insulin degludec for both type 1 and type 2 diabetes with PA. The PA request must include: a diagnosis code (E10.x for T1D or E11.x for T2D), documentation of an inadequate response or contraindication to at least one preferred formulary insulin (usually NPH or insulin glargine U-100), a current HbA1c, and prescriber attestation of medical necessity. [14] Processing time is 3 to 5 business days for standard PA and 24 hours for expedited PA when clinical urgency is documented.

Commercial insurance:

Step therapy requirements vary by plan, but the New York State step-therapy reform law (effective January 1, 2018, amended 2023) requires insurers to grant a step-therapy exception within 72 hours (24 hours for urgent situations) when the prescriber documents that the preferred drug is contraindicated, previously tried and failed, or likely to cause harm. [15] Hypoglycemia unawareness, confirmed nocturnal hypoglycemia events, or occupational hypoglycemia risk (e.g., a commercial driver) are commonly accepted clinical justifications in New York.

PA documentation checklist:

• Diagnosis with ICD-10 code
• HbA1c result with date
• Records of prior insulin trials and any adverse events
• Prescriber letter of medical necessity
• Any CGM data showing nocturnal hypoglycemia

The HealthRX care team handles PA submission and tracks appeals so patients do not have to manage the insurer portal independently.

Step 5: Fill Your Prescription at a New York Pharmacy

Retail and chain pharmacies:

CVS, Walgreens, Rite Aid, and independent pharmacies throughout New York stock or can order Tresiba FlexTouch pens. Calling ahead to confirm inventory of the specific concentration (U-100 vs. U-200) saves a trip. Tresiba is not interchangeable at the pharmacy counter with other basal insulins; pharmacists cannot substitute a different insulin without prescriber authorization under New York Education Law Section 6816-a. [16]

Mail-order and specialty pharmacy:

Express Scripts, Optum Rx, and CVS Caremark mail-order pharmacies ship to New York addresses and often offer 90-day supplies at lower copays than retail. Temperature-controlled shipping is standard; Tresiba pens arrive packed with insulated liners and ice packs. Most shipments within New York State arrive within 2 to 3 business days of prescription adjudication.

503A compounding pharmacies:

New York-licensed 503A compounding pharmacies may prepare insulin degludec preparations for individual patient prescriptions under strict New York State Board of Pharmacy oversight and United States Pharmacopeia (USP) Chapter 797 sterile compounding standards. [17] This pathway is used only when the commercial product is unavailable or the patient requires a non-standard concentration. The FDA does not consider compounded insulin degludec equivalent to the FDA-approved Tresiba product. [18]

Cost without insurance:

The list price for a box of five Tresiba U-100 FlexTouch pens (5 x 3 mL, 300 units each) is approximately $530 to $580 at New York retail pharmacies as of mid-2025. Novo Nordisk's My$99Insulin program caps out-of-pocket cost at $99 per 30-day supply for eligible commercially insured patients. [19] GoodRx and Cost Plus Drugs coupons may bring the price lower at select New York locations; prices vary by zip code.

Step 6: Transfer an Existing Tresiba Prescription to New York

Transferring a Tresiba prescription from another state to a New York pharmacy is straightforward for a refillable prescription. Under New York State law, retail pharmacies can accept transferred prescriptions for non-controlled drugs from out-of-state pharmacies. [16] The receiving pharmacist contacts the original pharmacy to verify the prescription. Mail-order pharmacies licensed in New York can also accept transfers.

If you are relocating to New York permanently, your out-of-state prescriber's prescription remains valid until the last refill is dispensed, but a New York-licensed prescriber must write any new or renewed prescription. The telehealth pathway described above means you can establish care with a New York provider the same day you need a renewal, without leaving your home.

Safety Considerations Specific to New York Patients

Insulin degludec carries an FDA black box warning for hypoglycemia. [1] The SWITCH 1 and SWITCH 2 trials, which enrolled type 1 and type 2 diabetes patients respectively, found statistically significantly lower rates of overall symptomatic hypoglycemia with degludec versus glargine U-100 (SWITCH 2: rate ratio 0.70 to 95% CI 0.61 to 0.80, P<0.001 for nocturnal hypoglycemia). [20]

New York City-based patients using the subway or commuting long hours should plan injection timing around consistent daily schedules when possible. The label's 8-hour dosing flexibility window helps, but skipping doses or doubling up is never recommended. [1] Patients on SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) co-prescribed with Tresiba should be aware of additive hypoglycemia risk, particularly during caloric restriction or increased physical activity. [21]

Driving regulations: the New York State DMV does not require automatic insulin-related reporting, but the ADA recommends that patients treat any blood glucose <70 mg/dL before driving and recheck 15 minutes after treatment before getting behind the wheel. [22]

Drug Interactions and Contraindications to Review Before Your Visit

Insulin degludec's glucose-lowering effect is enhanced by oral antidiabetic agents (metformin, sulfonylureas, meglitinides, GLP-1 receptor agonists, SGLT-2 inhibitors) and decreased by corticosteroids, thiazide diuretics, sympathomimetics, and some antipsychotics. [1] New York patients on atypical antipsychotics (commonly prescribed in psychiatric comorbidity populations) should have their basal insulin dose reviewed every 60 to 90 days given the metabolic effects of those agents on insulin sensitivity. [23]

Renal impairment does not require dose adjustment for insulin degludec specifically, but the frequency of hypoglycemia increases as GFR declines, because the kidneys clear insulin and glucose more slowly. [8] The ADA recommends more frequent glucose monitoring in patients with an eGFR <45 mL/min/1.73 m. [7]

Pregnancy: insulin degludec is FDA Pregnancy Category not assigned (post-2015 labeling framework). The label notes insufficient human data to establish risk. Most endocrinologists and the American College of Obstetricians and Gynecologists recommend switching to NPH insulin or insulin detemir (both with more extensive pregnancy safety data) when a patient becomes pregnant, unless the clinical benefit outweighs the uncertainty. [24] Women of reproductive age in New York considering pregnancy should discuss this with their HealthRX prescriber before conception.

What New York Patients Typically Pay Out of Pocket

Even with insurance, cost is a real barrier for many New York patients. A 2022 analysis published in JAMA Internal Medicine found that among commercially insured US patients, 14% reported insulin cost-related underuse in the prior 12 months. [25] New York State passed the Insulin Pricing Law (Public Health Law Section 280) capping commercial insurance copays for insulin at $100 per 30-day supply since 2020. [26] This cap applies to fully insured New York commercial plans but not self-insured employer plans regulated under ERISA.

For uninsured New York patients, the Novo Nordisk Patient Assistance Program (PAP) provides Tresiba at no cost to qualifying individuals with income at or below 400% of the federal poverty level. Applications are submitted online through the Novo Nordisk NovoCare program. [19]